PubMed · 7723520
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
P G Godwin. 1995-04-22. Ethics committees.. https://pubmed.ncbi.nlm.nih.gov/7723520/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Sarcomas of the head and neck are extremely rare, accounting for less than 1% of all neoplasms of the head and neck. These sarcomas arise in both soft tissues and bone and thus cannot be treated by a single approach. The clinical behavior of these tumors varies considerably. Patients with low-grade lesions are prone to local recurrence, whereas those with high-grade lesions develop both local recurrence and disseminated disease. An additional complicating factor is the multiple sites in which sarcomas may arise in the head and neck. All of these factors make it difficult to ascertain the optimal treatment approach for sarcomas. This article reviews the current literature (as well as the author's own experience) and provides a general treatment guideline for sarcomas of the head and neck.
Malignant neoplasms involving the temporal bone are a relatively rare and often misdiagnosed disease. Staging of temporal bone cancer has proven difficult because of the small number of patients with this condition, the various histopathologic and histologic findings reported, and a lack of randomized trials. Of the various staging systems that have been proposed, the Pittsburgh classification appears to be the most widely accepted. A retrospective study of 31 patients with temporal bone malignancy at the University of Arkansas for Medical Sciences has led us to propose a modification of the Pittsburgh classification for early-stage lesions. This modification places more emphasis on the site of disease in the canal and less on the size of the primary tumor or degree of bony invasion. This review discusses this staging system, the management of these tumors in a multidisciplinary team approach, reconstructive options, and auditory rehabilitation.
The clinically negative (N0) neck is defined by its absence of palpable or radiographically suspicious lymph nodes. Management of patients staged N0 is controversial. Clinical studies have lacked sufficient power and follow-up time to show a survival benefit for any particular option. Current options include observation, elective neck irradiation, and elective neck dissection. Treatment plans are based on treatment of the primary tumor and surgeon preference.